UltraGreen.ai ready to recalibrate US medical dye strategy

The company’s response will hinge on its rivals’ pricing, distribution, and customer offer.

UltraGreen.ai is prepared to adjust its commercial strategy as new competitors enter the US indocyanine green (ICG) market, with its response to depend on rivals’ pricing, distribution approach, and customer proposition.

ICG is a fluorescent medical dye used in diagnostic imaging and surgical procedures to help visualise blood flow and tissue.

CEO Ravinder Sajwan said in a filing that the company would determine its response once the commercial plans of new entrants become clearer.

“We believe it would be premature to speculate on their potential market impact or the specific actions UltraGreen may take in response,” he added.

The comments come as recent US regulatory approvals secured by new entrants have raised concerns among shareholders.

However, Sajwan noted that US Food and Drug Administration approval does not necessarily indicate a commercial launch, customer adoption, or market penetration.

“UltraGreen may be a relatively young public company, but we have been operating in the fluorescence-guided surgery for more than a decade,” he said.

Separately, the company is expanding beyond ICG through PerfusionWorks, which adds quantification and data capabilities to its fluorescence-guided surgery platform.

PerfusionWorks has completed its European Medical Device Regulation conformity assessment and is awaiting formal CE certification.

UltraGreen plans to pursue US FDA clearance for the platform after receiving the European certification.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia